Akari Therapeutics reported new preclinical results for AKTX-101, its TROP2-targeted ADC (antibody-drug conjugate, a targeted cancer therapy) carrying the PH1 RNA spliceosome-modulating payload, showing anti-tumor activity across urothelial cancer models that included advanced disease with limited response to Padcev and tumors that acquired resistance after Trodelvy treatment. In the UM-UC-14 metastatic urothelial carcinoma model, AKTX-101 produced statistically significant tumor growth inhibition versus vehicle while Padcev showed limited responsiveness. In tumors that resumed growth after initial Trodelvy treatment, switching to AKTX-101 slowed growth again, supporting Akari's view that payload sequencing may help address resistance tied to older microtubule and topoisomerase 1 payload classes rather than loss of the TROP2 target. The company said it is continuing IND-enabling work and aims to start a Phase 1 trial in mid-2027, while also expanding the PH1 platform through additional tumor-focused programs and strategic collaborations.